Anti-Myelin Oligodendrocyte Glycoprotein Encephalomyelitis and Extensive Longitudinal Transverse Myelitis Associated with Compound Heterozygous NLRP3 Missense Mutations in a Young ChildFunding None.
Acute disseminated encephalomyelitis in association with extensive longitudinal transverse myelitis is reported in a young child with positive anti-myelin oligodendrocyte glycoprotein (MOG) antibody with heterozygous NLRP3 missense mutations; p.(Arg488Lys) and p.(Ser159Ile). This case may well present an exceptional coincidence, but may describe a yet unrecognized feature of the spectrum of childhood onset cryopyrinopathies that contribute to the understanding of the genetic basis for anti-MOG antibody positive encephalomyelitis. Based on this observation, a larger scale study investigating the role of NLRP3 and other inflammasomes in this entity would provide important pathophysiological insights and potentially novel avenues for treatment.
This study received written patient consent from both parents.
Received: 23 June 2020
Accepted: 28 October 2020
26 December 2020 (online)
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Kuemmerle-Deschner JB, Ozen S, Tyrrell PN. et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann Rheum Dis 2017; 76 (06) 942-947
- 2 Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol 2019; 19 (08) 477-489
- 3 Theofani E, Semitekolou M, Morianos I, Samitas K, Xanthou G. Targeting NLRP3 inflammasome activation in severe asthma. J Clin Med 2019; 8 (10) 1615
- 4 Luo Y, Lu J, Ruan W, Guo X, Chen S. MCC950 attenuated early brain injury by suppressing NLRP3 inflammasome after experimental SAH in rats. Brain Res Bull 2019; 146: 320-326
- 5 Kuwar R, Rolfe A, Di L. et al. A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. J Neuroinflammation 2019; 16 (01) 81
- 6 Chatterjee S, Tao JQ. Reactive Oxygen Species activate the NLRP3 Inflammasomein a model of lung transplant. FASEB J 2019; 33 (1 supplement): 549-552
- 7 Ising C, Venegas C, Zhang S. et al. NLRP3 inflammasome activation drives tau pathology. Nature 2019; 575 (7784): 669-673
- 8 Tourkochristou E, Aggeletopoulou I, Konstantakis C, Triantos C. Role of NLRP3 inflammasome in inflammatory bowel diseases. World J Gastroenterol 2019; 25 (33) 4796-4804
- 9 Pham-Dinh D, Jones EP, Pitiot G. et al. Physical mapping of the human and mouse MOG gene at the distal end of the MHC class Ib region. Immunogenetics 1995; 42 (05) 386-391
- 10 della Gaspera B, Pham-Dinh D, Roussel G, Nussbaum JL, Dautigny A. Membrane topology of the myelin/oligodendrocyte glycoprotein. Eur J Biochem 1998; 258 (02) 478-484
- 11 Breithaupt C, Schubart A, Zander H. et al. Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein. Proc Natl Acad Sci U S A 2003; 100 (16) 9446-9451
- 12 Lebar R, Lubetzki C, Vincent C, Lombrail P, Boutry JM. The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin Exp Immunol 1986; 66 (02) 423-434
- 13 Marti Fernandez I, Macrini C, Krumbholz M. et al. The glycosylation site of myelin oligodendrocyte glycoprotein affects autoantibody recognition in a large proportion of patients. Front Immunol 2019; 10: 1189
- 14 Delarasse C, Della Gaspera B, Lu CW. et al. Complex alternative splicing of the myelin oligodendrocyte glycoprotein gene is unique to human and non-human primates. J Neurochem 2006; 98 (06) 1707-1717
- 15 Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease. J Neurol 2019; 266 (05) 1280-1286
- 16 Aróstegui JI, Aldea A, Modesto C. et al. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis Rheum 2004; 50 (12) 4045-4050
- 17 Aksentijevich I, Putnam CD, Remmers EF. et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007; 56 (04) 1273-1285
- 18 Kuemmerle-Deschner JB, Verma D, Endres T. et al. Clinical and molecular phenotypes of low-penetrance variants of NLRP3: diagnostic and therapeutic challenges. Arthritis Rheumatol 2017; 69 (11) 2233-2240
- 19 Levy R, Gérard L, Kuemmerle-Deschner J. et al; for PRINTO and Eurofever. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis 2015; 74 (11) 2043-2049
- 20 Tucker LB, Lamot L, Niemietz I. et al. Complexity in unclassified auto-inflammatory disease: a case report illustrating the potential for disease arising from the allelic burden of multiple variants. Pediatr Rheumatol Online J 2019; 17 (01) 70
- 21 Rieber N, Gavrilov A, Hofer L. et al. A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants. Clin Immunol 2015; 157 (01) 56-64
- 22 Schuh E, Lohse P, Ertl-Wagner B. et al. Expanding spectrum of neurologic manifestations in patients with NLRP3 low-penetrance mutations. Neurol Neuroimmunol Neuroinflamm 2015; 2 (04) e109